* Cassava Sciences Inc reported a quarterly adjusted loss of 58 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -61 cents. The mean expectation of two analysts for the quarter was for a loss of 88 cents per share. Wall Street expected results to range from $-1.37 to -39 cents per share.
* Reported revenue was zero; analysts expected zero.
* Cassava Sciences Inc's reported EPS for the quarter was a loss of 58 cents.
* The company reported a quarterly loss of $27.94 million.
* Cassava Sciences Inc shares had fallen by 9.7% this quarter and gained 18.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 107.1% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is "hold."
Wall Street's median 12-month price target for Cassava Sciences Inc is 116.00 This summary was machine generated from LSEG data November 7 at 02:28 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.88 -0.58 Beat
Jun. 30 2024 -0.40 0.13 Beat
Mar. 31 2024 -0.46
Dec. 31 2023 -0.52
Comments